JamesHardingMD

Gastrointestinal Cancer

Assistant Attending, Gastrointestinal Oncology Service, Early Drug Development Service, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Harding

Dr. James J. Harding is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. He specializes in Gastrointestinal Cancer with a clinical and research focus on liver and biliary tract cancers.

Office
Memorial Sloan Kettering Cancer Center
1275 York Ave
New York, NY 10065
Book by Phone+1(414) 269-3839
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2007 - 2010
Albert Einstein College of MedicineClass of 2007

Certifications & Licensure

NJ State Medical License 2019 - 2025
NY State Medical License 2008 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
Completed
Phase 2
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Start of enrollment: 2014 Mar 07
Completed
Phase 1, Phase 2
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma Start of enrollment: 2014 Nov 01
Terminated
Phase 1, Phase 2
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2014 Aug 07
Terminated
Phase 1
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Start of enrollment: 2015 Dec 07
Completed
Phase 3
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Start of enrollment: 2015 Dec 01
Completed
Phase 1
PF-06671008 Dose Escalation Study in Advanced Solid Tumors Start of enrollment: 2016 Apr 28
Terminated
Phase 1
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors Start of enrollment: 2016 Jun 20
Completed
Phase 1, Phase 2
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors Start of enrollment: 2017 Apr 12
Completed
Phase 1
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Start of enrollment: 2017 Apr 28
Active, not recruiting
Early Phase 1
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25
Terminated
Phase 1
Study of GNS561 in Patients With Liver Cancer Start of enrollment: 2018 Apr 04
Terminated
Phase 1, Phase 2
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Jan 10
Recruiting
Phase 2
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2020 Mar 11
Completed
Phase 1
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Start of enrollment: 2020 Oct 16
Active, not recruiting
Phase 1
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors Start of enrollment: 2017 Jun 01
Terminated
Phase 1, Phase 2
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) Start of enrollment: 2022 Jun 28
Terminated
Phase 1
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer Start of enrollment: 2022 May 05
Recruiting
Phase 1, Phase 2
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Start of enrollment: 2022 Apr 18
Active, not recruiting
Phase 1
Roles: Contact
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Start of enrollment: 2022 Nov 25
Recruiting
Phase 2
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Start of enrollment: 2023 Nov 09
Recruiting
Phase 1
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Start of enrollment: 2023 Mar 23
Recruiting
Phase 1, Phase 2
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Start of enrollment: 2024 Apr 30
Recruiting
Phase 3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Start of enrollment: 2023 Dec 04
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors.
Harding, J., Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Do-Youn Oh, Paul Severson, Betty Y Tam, Benjamin Garmezy, Mitesh J Borad, Shumei Kato, Cheng Quah, James ...> ;Cancer Research Communications. 2024 Apr 11
Immunotherapy: A Sharp Curve Turn at the Corner of Targeted Therapy in the Treatment of Biliary Tract Cancers.
Al Mahmasani, L., Harding, J., Abou-Alfa, G.> ;Hematology/oncology Clinics of North America. 2024 Feb 28
Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.
Harding, J., Sarah M McIntyre, William A Preston, Henry Walch, Jeremy Sharib, Ritika Kundra, Carlie Sigel, Michael E Lidsky, Peter J Allen, Michael A Morse, Wei Chen, ...> ;JCO Precision Oncology. 2024 Feb 1
1 citations
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami, P., Diab, Y., Jarnagin, W., Hajj, J., El Homsi, M., Khalil, D., Azhari, H., Abou-Alfa, G., Harding, J., Ma, J., Reyngold, M., Crane, C., Hajj, C.> ;International Journal of Molecular Sciences. 2023 Nov 26
ASO Visual Abstract: Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.
Stijn Franssen, Jessica J Holster, Joshua S Jolissaint, Lynn E Nooijen, Andrea Cercek, Michael I D'Angelica, Marjolein Y V Homs, Alice C Wei, Vinod P Balachandran, Jef...> ;Annals of Surgical Oncology. 2024 Feb 1
Safety and Efficacy of Hepatic Artery Embolization in Heavily Treated Patients with Intrahepatic Cholangiocarcinoma: Analysis of Clinicopathological and Radiographic P...
Sara Velayati, Ahmed Elsakka, Ken Zhao, Joseph P Erinjeri, Brett Marinelli, Mohamed Soliman, Olivier Chevallier, Etay Ziv, Lynn A Brody, Constantinos T Sofocleous, Ste...> ;Current Oncology. 2023 Oct 18
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.
Stijn Franssen, Jessica J Holster, Joshua S Jolissaint, Lynn E Nooijen, Andrea Cercek, Michael I D'Angelica, Marjolein Y V Homs, Alice C Wei, Vinod P Balachandran, Jef...> ;Annals of Surgical Oncology. 2024 Jan 1
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Darren Cowzer, Jessica B White, Joanne F Chou, Pin-Jung Chen, Tae-Hyung Kim, Danny N Khalil, Imane H El Dika, Katrina Columna, Amin Yaqubie, Joseph S Light, Jinru Shia...> ;JCO Precision Oncology. 2023 Sep 1
Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?
Canestraro, J., Diamond, E., Francis, J., Foulsham, W., Harding, J., Drilon, A., Abramson, D.> ;Ocular Oncology and Pathology. 2023 Aug 1
18 citations
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
James J Harding, Jia Fan, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Phillippe Metges, Jie'er ...> ;The Lancet. Oncology. 2023 Jul 1
Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival.
Kevin C Soares, Joshua S Jolissaint, Sarah M McIntyre, Kenneth P Seier, Mithat Gönen, Carlie Sigel, Naaz Nasar, Andrea Cercek, James J Harding, Nancy E Kemeny, Louise ...> ;Cancer Medicine. 2023 Jun 1
3 citations
Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma.
Perla Chami, William Jarnagin, Ghassan K Abou-Alfa, James Harding, Neal Kim, Haibo Lin, Maria El Homsi, Christopher Crane, Carla Hajj> ;Cancers. 2023 Mar 14
2 citations
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation.
Bruno Almeida Costa, Paulino Tallón de Lara, Wungki Park, Fergus Keane, James J Harding, Danny N Khalil> ;Oncology Research and Treatment. 2023 Jan 1
2 citations
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.
James J Harding, Christiane Jungels, Jean-Pascal Machiels, David C Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K Abou...> ;Targeted Oncology. 2023 Mar 1
10 citations
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
8 citations
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry.
Enaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, Brook A Quist, Diego Lopez de Castilla, Charles Fix, Kahlil Chan, Jing Shi, Michael G Walker, Jennifer F Kherani...> ;The Journal of Applied Laboratory Medicine. 2023 May 4
10 citations
Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.
Tiago Biachi de Castria, Danny N Khalil, James J Harding, Eileen M O'Reilly, Ghassan K Abou-Alfa> ;Future Oncology. 2022 Oct 1
4 citations
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.
Nicolas A Giraldo, Esther Drill, Baby A Satravada, Imane El Dika, A Rose Brannon, Josephine Dermawan, Abhinita Mohanty, Kerem Ozcan, Debyani Chakravarty, Ryma Benayed,...> ;Clinical Cancer Research. 2022 Dec 15
Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma.
Binbin Zheng-Lin, David M Faleck, James J Harding> ;JAMA Oncology. 2022 Nov 1
14 citations
Rational development of combination therapies for biliary tract cancers.
James J Harding, Danny N Khalil, Luca Fabris, Ghassan K Abou-Alfa> ;Journal of Hepatology. 2023 Jan 1
4 citations
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
James J Harding, Ahmad Awada, Gael Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, Christelle Ansaldi, Madani Rachid, Soraya Mezouar, Agnes Menut,...> ;Liver Cancer. 2022 Jun 1
4 citations
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
James J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T Hooper, Cris Kamperschroer, Steven I Max, Allison Moreau,...> ;Frontiers in Immunology. 2022 Jan 1
7 citations
Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments.
Darren Cowzer, James J Harding> ;Cancers. 2022 Apr 1
5 citations
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
Dazhi Liu, Michael A Weintraub, Christine Garcia, Marcus D Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J Harding, Stephen Harnicar, Alexander Drilon, Komal Jhav...> ;Cancer Medicine. 2022 Apr 1
15 citations
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical Cancer Research. 2022 May 13
Join now to see all

Lectures

A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular car...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepato...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Treatment Options for Advanced HCC Patients Who Are Not Eligible for IO First LineMarch 14th, 2023
Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of Its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019July 3rd, 2019
Anti–TIM-3 Antibody Well Tolerated as Monotherapy and in Combination with Anti–PD-L1 AntibodyApril 10th, 2019
Join now to see all